Manuela Battaglia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9352837/publications.pdf

Version: 2024-02-01

103 papers	10,368 citations	53789 45 h-index	33889 99 g-index
107 all docs	107 docs citations	107 times ranked	12221 citing authors

#	Article	IF	Citations
1	Exocrine pancreas function is impaired in adult relatives of patients with type 1 diabetes. Acta Diabetologica, 2022, 59, 473-479.	2.5	3
2	Circulating platelet-neutrophil aggregates characterize the development of type 1 diabetes in humans and NOD mice. JCI Insight, 2022, 7, .	5.0	18
3	Identifying the â€˜Achilles heelâ€™ of type 1 diabetes. Clinical and Experimental Immunology, 2021, 204, 167-178.	2.6	3
4	Impaired exocrine pancreatic function in different stages of type 1 diabetes. BMJ Open Diabetes Research and Care, 2021, 9, e001158.	2.8	13
5	Altered Frequency and Phenotype of HLA-G-Expressing DC-10 in Type 1 Diabetes Patients at Onset and in Subjects at Risk to Develop the Disease. Frontiers in Immunology, 2021, 12, 750162.	4.8	4
6	CD4+CD25+CD127hi cell frequency predicts disease progression in type 1 diabetes. JCI Insight, 2021, 6, .	5.0	16
7	Reduced Follicular Regulatory T Cells in Spleen and Pancreatic Lymph Nodes of Patients With Type 1 Diabetes. Diabetes, 2021, 70, 2892-2902.	0.6	12
8	Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care, 2020, 43, 5-12.	8.6	220
9	Reduced PD-1 expression on circulating follicular and conventional FOXP3+ Treg cells in children with new onset type 1 diabetes and autoantibody-positive at-risk children. Clinical Immunology, 2020, 211, 108319.	3.2	16
10	Key role of macrophages in tolerance induction via T regulatory type 1 (Tr1) cells. Clinical and Experimental Immunology, 2020, 201, 222-230.	2.6	9
11	Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function. Journal of Translational Medicine, 2019, 17, 250.	4.4	4
12	Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. Diabetes, 2019, 68, 1267-1276.	0.6	80
13	Neutrophils and type 1 diabetes: current knowledge and suggested future directions. Current Opinion in Endocrinology, Diabetes and Obesity, 2019, 26, 201-206.	2.3	28
14	Tr1 cell immunotherapy promotes transplant tolerance via de novo Tr1 cell induction in mice and is safe and effective during acute viral infection. European Journal of Immunology, 2018, 48, 1389-1399.	2.9	17
15	Islet-reactive CD8 ⁺ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. Science Immunology, 2018, 3, .	11.9	171
16	The Biology of T Regulatory Type 1 Cells and Their Therapeutic Application in Immune-Mediated Diseases. Immunity, 2018, 49, 1004-1019.	14.3	230
17	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves Î²-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care, 2018, 41, 1917-1925.	8.6	114
18	A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. Diabetes Care, 2018, 41, 1887-1894.	8.6	104

#	Article	IF	Citations
19	Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. JCI Insight, 2018, 3, .	5.0	85
20	Murine Pancreatic Islets Transplantation under the Kidney Capsule. Bio-protocol, 2018, 8, e2743.	0.4	4
21	Protein tyrosine phosphatase PTPN22 has dual roles in promoting pathogen versus homeostaticâ€driven CD8 Tâ€cell responses. Immunology and Cell Biology, 2017, 95, 121-128.	2.3	10
22	IL-10 Receptor Signaling Is Essential for TR1 Cell Function In Vivo. Journal of Immunology, 2017, 198, 1130-1141.	0.8	108
23	Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes. Nature Immunology, 2017, 18, 1321-1331.	14.5	217
24	Regulatory T-cells from pancreatic lymphnodes of patients with type-1 diabetes express increased levels of microRNA miR-125a-5p that limits CCR2 expression. Scientific Reports, 2017, 7, 6897.	3.3	53
25	Understanding and preventing type 1 diabetes through the unique working model of TrialNet. Diabetologia, 2017, 60, 2139-2147.	6.3	59
26	Generation of donor-specific Tr1 cells to be used after kidney transplantation and definition of the timing of their in vivo infusion in the presence of immunosuppression. Journal of Translational Medicine, 2017, 15, 40.	4.4	39
27	Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection. Frontiers in Immunology, 2017, 8, 811.	4.8	10
28	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers in Immunology, 2017, 8, 1844.	4.8	43
29	The â€œUnusual Suspectsâ€• in Allograft Rejection: Will T Regulatory Cell Therapy Arrest Them?. Current Transplantation Reports, 2016, 3, 221-226.	2.0	0
30	Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes. Stem Cells, 2016, 34, 809-819.	3.2	10
31	Loss of immune tolerance to IL-2 in type 1 diabetes. Nature Communications, 2016, 7, 13027.	12.8	28
32	Generation of Donor-specific T Regulatory Type 1 Cells From Patients on Dialysis for Cell Therapy After Kidney Transplantation. Transplantation, 2015, 99, 1582-1589.	1.0	24
33	All in (IL-) 1?. Transplantation, 2015, 99, 2235-2236.	1.0	0
34	Immune Depletion in Combination with Allogeneic Islets Permanently Restores Tolerance to Self-Antigens in Diabetic NOD Mice. PLoS ONE, 2015, 10, e0142318.	2.5	4
35	Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia, 2015, 29, 396-405.	7.2	114
36	PTPN22 controls virally-induced autoimmune diabetes by modulating cytotoxic T lymphocyte responses in an epitope-specific manner. Clinical Immunology, 2015, 156, 98-108.	3.2	7

#	Article	IF	Citations
37	Heterogeneous CD3 Expression Levels in Differing T Cell Subsets Correlate with the In Vivo Anti-CD3â€"Mediated T Cell Modulation. Journal of Immunology, 2015, 194, 2117-2127.	0.8	23
38	Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes. Diabetes, 2015, 64, 3873-3884.	0.6	22
39	Lack of the protein tyrosine phosphatase PTPN22 strengthens transplant tolerance to pancreatic islets in mice. Diabetologia, 2015, 58, 1319-1328.	6.3	9
40	The Streetlight Effect in Type 1 Diabetes. Diabetes, 2015, 64, 1081-1090.	0.6	66
41	Hurdles in therapy with regulatory T cells. Science Translational Medicine, 2015, 7, 304ps18.	12.4	136
42	Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset?. Current Diabetes Reports, 2015, 15, 115.	4.2	11
43	Abnormalities of the Exocrine Pancreas in Type 1 Diabetes. Current Diabetes Reports, 2015, 15, 79.	4.2	90
44	CXCR1/2 Inhibition Blocks and Reverses Type 1 Diabetes in Mice. Diabetes, 2015, 64, 1329-1340.	0.6	70
45	Combination of an Antigen-Specific Therapy and an Immunomodulatory Treatment to Simultaneous Block Recurrent Autoimmunity and Alloreactivity in Non-Obese Diabetic Mice. PLoS ONE, 2015, 10, e0127631.	2.5	9
46	Experiments by nature: lessons on type 1 diabetes. Tissue Antigens, 2014, 83, 1-9.	1.0	11
47	Calcineurin Inhibitor-Free Immunosuppressive Regimen in Type 1 Diabetes Patients Receiving Islet Transplantation. Transplantation, 2014, 98, 1301-1309.	1.0	21
48	Neutrophils and type 1 autoimmune diabetes. Current Opinion in Hematology, 2014, 21, 8-15.	2.5	38
49	Tr1 Cells and the Counter-Regulation of Immunity: Natural Mechanisms and Therapeutic Applications. Current Topics in Microbiology and Immunology, 2014, 380, 39-68.	1.1	191
50	The protein tyrosine phosphatase PTPN22 controls forkhead box protein 3 T regulatory cell induction but is dispensable for T helper type 1 cell polarization. Clinical and Experimental Immunology, 2014, 178, 178-189.	2.6	26
51	Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity. Clinical Immunology, 2013, 149, 556-565.	3.2	58
52	Reduction of Circulating Neutrophils Precedes and Accompanies Type 1 Diabetes. Diabetes, 2013, 62, 2072-2077.	0.6	177
53	Transplant Tolerance to Pancreatic Islets Is Initiated in the Graft and Sustained in the Spleen. American Journal of Transplantation, 2013, 13, 1963-1975.	4.7	44
54	Standardization in flow cytometry: correct sample handling as a priority. Nature Reviews Immunology, 2012, 12, 864-864.	22.7	10

#	Article	IF	Citations
55	Expanding Human T Regulatory Cells with the mTOR-Inhibitor Rapamycin. Methods in Molecular Biology, 2012, 821, 279-293.	0.9	53
56	Type 1 regulatory T (Tr1) cells: from the bench to the bedside. Journal of Translational Medicine, 2012, 10, .	4.4	1
57	Immune intervention with T regulatory cells: Past lessons and future perspectives for type 1 diabetes. Seminars in Immunology, 2011, 23, 182-194.	5.6	46
58	Rapamycin Combined with Anti-CD45RB mAb and IL-10 or with G-CSF Induces Tolerance in a Stringent Mouse Model of Islet Transplantation. PLoS ONE, 2011, 6, e28434.	2.5	36
59	Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood, 2011, 118, 6772-6782.	1.4	132
60	Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells. Haematologica, 2011, 96, 1357-1365.	3.5	79
61	Th17 Cells Express Interleukin-10 Receptor and Are Controlled by Foxp3âˆ’ and Foxp3+ Regulatory CD4+ T Cells in an Interleukin-10-Dependent Manner. Immunity, 2011, 34, 554-565.	14.3	529
62	Expansion of Th17 Cells and Functional Defects in T Regulatory Cells Are Key Features of the Pancreatic Lymph Nodes in Patients With Type 1 Diabetes. Diabetes, 2011, 60, 2903-2913.	0.6	199
63	Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10â€“dependent ILT4/HLA-G pathway. Blood, 2010, 116, 935-944.	1.4	481
64	Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. Journal of Neuroimmunology, 2010, 220, 52-63.	2.3	88
65	Potential T regulatory cell therapy in transplantation: how far have we come and how far can we go?. Transplant International, 2010, 23, 761-770.	1.6	22
66	Co-Graft of Allogeneic Immune Regulatory Neural Stem Cells (NPC) and Pancreatic Islets Mediates Tolerance, while Inducing NPC-Derived Tumors in Mice. PLoS ONE, 2010, 5, e10357.	2.5	30
67	Antigen-Specific Dependence of Tr1-Cell Therapy in Preclinical Models of Islet Transplant. Diabetes, 2010, 59, 433-439.	0.6	72
68	Modulation of Early Inflammatory Reactions to Promote Engraftment and Function of Transplanted Pancreatic Islets in Autoimmune Diabetes. Advances in Experimental Medicine and Biology, 2010, 654, 725-747.	1.6	25
69	Rapamycin Prevents and Breaks the Anti-CD3â€“Induced Tolerance in NOD Mice. Diabetes, 2009, 58, 875-881.	0.6	40
70	Immune Depletion With Cellular Mobilization Imparts Immunoregulation and Reverses Autoimmune Diabetes in Nonobese Diabetic Mice. Diabetes, 2009, 58, 2277-2284.	0.6	68
71	The Tregs' world according to GARP. European Journal of Immunology, 2009, 39, 3296-3300.	2.9	38
72	Comment on M. Guillotâ€Delost et al. (2008;10:834â€846): Clinicalâ€grade preparation of human natural regulatory T cells encoding the thymidine kinase suicide gene as a safety gene. Journal of Gene Medicine, 2009, 11, 180-181.	2.8	1

#	Article	IF	Citations
73	Autoimmune diabetic patients undergoing allogeneic islet transplantation: are we ready for a regulatory T-cell therapy?. Immunology Letters, 2009, 127, 1-7.	2.5	11
74	The Fate of Human Treg Cells. Immunity, 2009, 30, 763-765.	14.3	33
75	In vivo neutralization of inflammatory cytokines might not be necessary for regulatory T-cell immunotherapy. Nature Reviews Immunology, 2008, 8, 1-1.	22.7	1
76	STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25â^' effector T cells. International Immunology, 2008, 20, 421-431.	4.0	166
77	Rapamycin Monotherapy in Patients With Type 1 Diabetes Modifies CD4+CD25+FOXP3+ Regulatory T-Cells. Diabetes, 2008, 57, 2341-2347.	0.6	128
78	Reâ€Establishing Immune Tolerance in Type 1 Diabetes via Regulatory T Cells. Novartis Foundation Symposium, 2008, 292, 174-186.	1.1	8
79	Human Type 1 T Regulatory Cells. , 2008, , 455-471.		0
80	WASP regulates suppressor activity of human and murine CD4+CD25+FOXP3+ natural regulatory T cells. Journal of Experimental Medicine, 2007, 204, 369-380.	8.5	167
81	The immune response to lentiviral-delivered transgene is modulated in vivo by transgene-expressing antigen-presenting cells but not by CD4+CD25+ regulatory T cells. Blood, 2007, 110, 1788-1796.	1.4	35
82	Relevance of Hyperglycemia on the Timing of Functional Loss of Allogeneic Islet Transplants: Implication for Mouse Model. Transplantation, 2007, 83, 167-173.	1.0	29
83	Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nature Reviews Immunology, 2007, 7, 585-598.	22.7	461
84	A hypomorphic R229Q Rag2 mouse mutant recapitulates human Omenn syndrome. Journal of Clinical Investigation, 2007, 117, 1260-1269.	8.2	97
85	Induction of Tolerance in Type 1 Diabetes via Both CD4+CD25+ T Regulatory Cells and T Regulatory Type 1 Cells. Diabetes, 2006, 55, 1571-1580.	0.6	151
86	Allogeneic mesoangioblasts give rise to alpha-sarcoglycan expressing fibers when transplanted into dystrophic mice. Experimental Cell Research, 2006, 312, 3872-3879.	2.6	30
87	Tr1 cells: From discovery to their clinical application. Seminars in Immunology, 2006, 18, 120-127.	5.6	246
88	Interleukinâ€10â€secreting type 1 regulatory T cells in rodents and humans. Immunological Reviews, 2006, 212, 28-50.	6.0	1,071
89	Induction of Transplantation Tolerance via Regulatory T Cells. Inflammation and Allergy: Drug Targets, 2006, 5, 157-165.	1.8	15
90	Rapamycin Promotes Expansion of Functional CD4+CD25+FOXP3+ Regulatory T Cells of Both Healthy Subjects and Type 1 Diabetic Patients. Journal of Immunology, 2006, 177, 8338-8347.	0.8	643

#	Article	IF	Citations
91	Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes, 2006, 55, 40-9.	0.6	72
92	Regulatory T cells: prospective for clinical application in hematopoietic stem cell transplantation. Current Opinion in Hematology, 2005, 12, 451-456.	2.5	18
93	Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood, 2005, 105, 4743-4748.	1.4	1,046
94	Platelet Factor 4 Differentially Modulates CD4+CD25+ (Regulatory) versus CD4+CD25â^' (Nonregulatory) T Cells. Journal of Immunology, 2005, 174, 2680-2686.	0.8	103
95	IL-10-Producing T Regulatory Type 1 Cells and Oral Tolerance. Annals of the New York Academy of Sciences, 2004, 1029, 142-153.	3.8	88
96	The role of cytokines (and not only) in inducing and expanding T regulatory type 1 cells.. Transplantation, 2004, 77, S16-S18.	1.0	26
97	Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood, 2004, 103, 3700-3709.	1.4	206
98	The role of interleukin 10 in the control of autoimmunity. Journal of Autoimmunity, 2003, 20, 269-272.	6.5	42
99	Human CD25+CD4+ T Suppressor Cell Clones Produce Transforming Growth Factor Î², but not Interleukin 10, and Are Distinct from Type 1 T Regulatory Cells. Journal of Experimental Medicine, 2002, 196, 1335-1346.	8.5	407
100	Beyond the usual suspects: a cholinergic route for panic attacks. Molecular Psychiatry, 2002, 7, 239-246.	7.9	25
101	Overlap of direct and indirect alloreactive T-cell repertoires when MHC polymorphism is limited to the peptide binding groove. Human Immunology, 2002, 63, 91-100.	2.4	5
102	The puzzling world of murine T regulatory cells. Microbes and Infection, 2002, 4, 559-566.	1.9	30
103	Beyond the usual suspects: a cholinergic route for panic attacks. , 0, .		1